Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2012 (2012), Article ID 183252, 3 pages
Case Report

Neuroleptic Malignant Syndrome Caused by a Combination of Carbamazepine and Amitriptyline

1Center For Neurology, Fairfax, VA 22031, USA
2Department of Neuroscience, King Khaled Hospital, 81442 Hail, Saudi Arabia
3Qassim University, Buraydah 51497, Saudi Arabia

Received 5 June 2012; Accepted 27 June 2012

Academic Editors: A. E. Cavanna and C.-C. Huang

Copyright © 2012 A. Bruce Janati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Delay, P. Pichot, T. Lemperiere, B. Elissalde, and F. Peigne, “A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses,” Annales Médico-Psychologiques, vol. 118, pp. 145–152, 1960. View at Google Scholar · View at Scopus
  2. J. R. Carbone, “The neuroleptic malignant and serotonin syndromes,” Emergency Medicine Clinics of North America, vol. 18, no. 2, pp. 317–325, 2000. View at Google Scholar · View at Scopus
  3. S. N. Caroff and S. C. Mann, “Neuroleptic malignant syndrome,” Psychopharmacology Bulletin, vol. 24, no. 1, pp. 25–29, 1988. View at Google Scholar · View at Scopus
  4. N. B. Thomas, “Neuroleptic malignant syndrome: a brief review,” Hospital Physician, pp. 58–63, 2002. View at Google Scholar
  5. C. Kawanishi, T. Hanihara, Y. Maruyama et al., “Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B,” Psychiatric Genetics, vol. 7, no. 3, pp. 127–129, 1997. View at Google Scholar · View at Scopus
  6. C. Kawanishi, T. Hanihara, Y. Shimoda et al., “Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT(1A) and 5-HT(2A) receptor genes,” American Journal of Psychiatry, vol. 155, no. 9, pp. 1275–1277, 1998. View at Google Scholar · View at Scopus
  7. A. Janati and R. T. Webb, “Successful treatment of neuroleptic malignant syndrome with bromocriptine,” Southern Medical Journal, vol. 79, no. 12, pp. 1567–1571, 1986. View at Google Scholar · View at Scopus
  8. S. Shankar, A. Sofia, S. Kripa, and G. Hany, “A case report of neuroleptic malignant syndrome,” BMJ Case Reports. In press. View at Publisher · View at Google Scholar
  9. B. M. Kerr, K. E. Thummel, C. J. Wurden et al., “Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation,” Biochemical Pharmacology, vol. 47, no. 11, pp. 1969–1979, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. O. V. Olesen and K. Linnet, “Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes,” Pharmacology, vol. 55, no. 5, pp. 235–243, 1997. View at Google Scholar · View at Scopus
  11. E. Leinonen, P. Lillsunde, V. Laukkanen, and P. Ylitalo, “Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients,” Journal of Clinical Psychopharmacology, vol. 11, no. 5, pp. 313–318, 1991. View at Google Scholar · View at Scopus